Back

Initial safety of targeted immune activation with the amyloid depleter ALXN2220

12 May 2024 (11:00 - 11:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 5 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Thibaud Damy

University Hospital Henri Mondor, Creteil (France)

6 More presentations in this session

Presentation thumbnail
Renin-angiotensin-aldosterone system inhibitor discontinuation and its impact on one-year mortality in heart failure patients with acute kidney injury: a propensity matched analysis
Doctor D. Feldman (Newark, US)
Abstract Slides Video
Presentation thumbnail
Deformation Imaging by Strain in Chronic heart failure Over gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 inhibitors (DISCOVER SGLT2i)
Doctor A. Stefanini (Siena, IT)
Abstract Slides Video
Presentation thumbnail
Age-stratified and sex-stratified effect of angiotensin receptor-neprilysin inhibitor in heart failure with reduced ejection fraction-data from PARADE-HF: nationwide medication adherence study
Doctor M. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
Safety, tolerability, and efficacy of uptitration of guideline-directed medical therapy for acute heart failure stratified by baseline risk
Doctor A. Chang (San Francisco, US)
Abstract Slides Video
Presentation thumbnail
Representation of frailty in contemporary trials of heart failure medications: a systematic review and dose-response meta-analysis
Doctor D. Rodolico (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 5

The Event

Event poster

Heart Failure 2024

12 May 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Tolerability of continued treatment with ATTR depleter ALXN2220 in the open-label extension of Phase 1 study NI006-101
thumbnail
Congress Presentation
Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac amyloid transthyretin: results of treatment beyond 12 months in the open-label extension of study NI006-101
thumbnail
Congress Presentation
New therapeutic opportunities: from mechanisms to clinical practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources